|
1
|
Knutson KL, Karyampudi L, Lamichhane P and
Preston C: Targeted immune therapy of ovarian cancer. Cancer
Metastasis Rev. 34:53–74. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Suh DH, Kim JW, Kim K, Kim HJ and Lee KH:
Major clinical research advances in gynecologic cancer in 2012. J
Gynecol Oncol. 24:66–82. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Zhou Y, Wang M, Wu J, Jie Z, Chang S and
Shuang T: The clinicopathological significance of miR-1307 in
chemotherapy resistant epithelial ovarian cancer. J Ovarian Res.
8:232015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Aletti GD, Gallenberg MM, Cliby WA, Jatoi
A and Hartmann LC: Current management strategies for ovarian
cancer. Mayo Clin Proc. 82:pp. 751–770. 2007; View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Schwartz PE: Current diagnosis and
treatment modalities for ovarian cancer. Cancer Treat Res.
107:99–118. 2002.PubMed/NCBI
|
|
7
|
Ji K, Ye L, Mason MD and Jiang WG: The
Kiss-1/Kiss-1R complex as a negative regulator of cell motility and
cancer metastasis (Review). Int J Mol Med. 32:747–754.
2013.PubMed/NCBI
|
|
8
|
Fan Y, Fan J, Huang L, Ye M, Huang Z, Wang
Y, Li Q and Huang J: Increased expression of microRNA-196a predicts
poor prognosis in human ovarian carcinoma. Int J Clin Exp Pathol.
8:4132–4137. 2015.PubMed/NCBI
|
|
9
|
Rutten MJ, van de Vrie R, Bruining A,
Spijkerboer AM, Mol BW, Kenter GG and Buist MR: Predicting surgical
outcome in patients with International Federation of Gynecology and
Obstetrics stage III or IV ovarian cancer using computed
tomography: A systematic review of prediction models. Int J Gynecol
Cancer. 25:407–415. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Luo J, Zhou J, Cheng Q, Zhou C and Ding Z:
Role of microRNA-133a in epithelial ovarian cancer pathogenesis and
progression. Oncol Lett. 7:1043–1048. 2014.PubMed/NCBI
|
|
11
|
Katz B, Tropé CG, Reich R and Davidson B:
MicroRNAs in Ovarian Cancer. Hum Pathol. 46:1245–1256. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Zhang S, Lu Z, Unruh AK, Ivan C, Baggerly
KA, Calin GA, Li Z, Bast RC Jr and Le XF: Clinically relevant
microRNAs in ovarian cancer. Mol Cancer Res. 13:393–401. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lee RC, Feinbaum RL and Ambros V: The C.
elegans heterochronic gene lin-4 encodes small RNAs with antisense
complementarity to lin-14. Cell. 75:843–854. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Di Leva G and Croce CM: miRNA profiling of
cancer. Curr Opin Genet Dev. 23:3–11. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Shah AA, Leidinger P, Blin N and Meese E:
miRNA: Small molecules as potential novel biomarkers in cancer.
Curr Med Chem. 17:4427–4432. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Jankovic R, Radulovic S and
Brankovic-Magic M: siRNA and miRNA for the treatment of cancer. J
BUON. 14 Suppl 1:S43–S49. 2009.PubMed/NCBI
|
|
17
|
Li X, Abdel-Mageed AB, Mondal D and Kandil
E: MicroRNA expression profiles in differentiated thyroid cancer, a
review. Int J Clin Exp Med. 6:74–80. 2013.PubMed/NCBI
|
|
18
|
Hwang HW and Mendell JT: MicroRNAs in cell
proliferation, cell death, and tumorigenesis. Br J Cancer. 96
Suppl:R40–R44. 2007.PubMed/NCBI
|
|
19
|
Zhu W, Zhu D, Lu S, Wang T, Wang J, Jiang
B, Shu Y and Liu P: miR-497 modulates multidrug resistance of human
cancer cell lines by targeting BCL2. Med Oncol. 29:384–391. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Dong LL, Chen LM, Wang WM and Zhang LM:
Decreased expression of microRNA-124 is an independent unfavorable
prognostic factor for patients with breast cancer. Diagn Pathol.
10:452015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu K, Liu S, Zhang W, Jia B, Tan L, Jin Z
and Liu Y: miR-494 promotes cell proliferation, migration and
invasion and increased sorafenib resistance in hepatocellular
carcinoma by targeting PTEN. Oncol Rep. 34:1003–1010.
2015.PubMed/NCBI
|
|
23
|
Sun HB, Chen X, Ji H, Wu T, Lu HW, Zhang
Y, Li H and Li YM: miR-494 is an independent prognostic factor and
promotes cell migration and invasion in colorectal cancer by
directly targeting PTEN. Int J Oncol. 45:2486–2494. 2014.PubMed/NCBI
|
|
24
|
Wang J, Chen H, Liao Y, Chen N, Liu T and
Zhang H and Zhang H: Expression and clinical evidence of miR-494
and PTEN in non-small cell lung cancer. Tumour Biol. 36:6965–6972.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
He W, Li Y, Chen X, Lu L, Tang B, Wang Z,
Pan Y, Cai S, He Y and Ke Z: miR-494 acts as an anti-oncogene in
gastric carcinoma by targeting c-myc. J Gastroenterol Hepatol.
29:1427–1434. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Shen PF, Chen XQ, Liao YC, Chen N, Zhou Q,
Wei Q, Li X, Wang J and Zeng H: MicroRNA-494-3p targets CXCR4 to
suppress the proliferation, invasion, and migration of prostate
cancer. Prostate. 74:756–767. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Zhang R, Chen X, Zhang S, Zhang X, Li T,
Liu Z, Wang J, Zang W, Wang Y, Du Y and Zhao G: Upregulation of
miR-494 inhibits cell growth and invasion and induces cell
apoptosis by targeting cleft lip and palate transmembrane 1-like in
esophageal squamous cell carcinoma. Dig Dis Sci. 60:1247–1255.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liborio-Kimura TN, Jung HM and Chan EK:
miR-494 represses HOXA10 expression and inhibits cell proliferation
in oral cancer. Oral Oncol. 51:151–157. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Song L, Liu D, Wang B, He J, Zhang S, Dai
Z, Ma X and Wang X: miR-494 suppresses the progression of breast
cancer in vitro by targeting CXCR4 through the Wnt/β-catenin
signaling pathway. Oncol Rep. 34:525–531. 2015.PubMed/NCBI
|
|
30
|
Liu Y, Li X, Zhu S, Zhang JG, Yang M, Qin
Q, Deng SC, Wang B, Tian K, Liu L, et al: Ectopic expression of
miR-494 inhibited the proliferation, invasion and chemoresistance
of pancreatic cancer by regulating SIRT1 and c-Myc. Gene Ther.
22:729–738. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Li J, Wang L, Liu Z, Zu C, Xing F, Yang P,
Yang Y, Dang X and Wang K: MicroRNA-494 inhibits cell proliferation
and invasion of chondrosarcoma cells in vivo and in vitro by
directly targeting SOX9. Oncotarget. 6:26216–26229. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chen B, Hou Z, Li C and Tong Y: MiRNA-494
inhibits metastasis of cervical cancer through Pttg1. Tumour Biol.
36:7143–7149. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Guarente L and Picard F: Calorie
restriction-the SIR2 connection. Cell. 120:473–482. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Blander G and Guarente L: The Sir2 family
of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hida Y, Kubo Y, Murao K and Arase S:
Strong expression of a longevity-related protein, SIRT1, in Bowen's
disease. Arch Dermatol Res. 299:103–106. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Huffman DM, Grizzle WE, Bamman MM, Kim JS,
Eltoum IA, Elgavish A and Nagy TR: SIRT1 is significantly elevated
in mouse and human prostate cancer. Cancer Res. 67:6612–6618. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kuzmichev A, Margueron R, Vaquero A,
Preissner TS, Scher M, Kirmizis A, Ouyang X, Brockdorff N,
Abate-Shen C, Farnham P and Reinberg D: Composition and histone
substrates of polycomb repressive group complexes change during
cellular differentiation. Proc Natl Acad Sci USA. 102:pp.
1859–1864. 2005; View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Chen WY, Wang DH, Yen RC, Luo J, Gu W and
Baylin SB: Tumor suppressor HIC1 directly regulates SIRT1 to
modulate p53-dependent DNA-damage responses. Cell. 123:437–448.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Yamakuchi M, Ferlito M and Lowenstein CJ:
miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci
USA. 105:pp. 13421–13426. 2008; View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Lai L, Yan L, Gao S, Hu CL, Ge H, Davidow
A, Park M, Bravo C, Iwatsubo K, Ishikawa Y, et al: Type 5 adenylyl
cyclase increases oxidative stress by transcriptional regulation of
manganese superoxide dismutase via the SIRT1/FoxO3a pathway.
Circulation. 127:1692–1701. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Mouchiroud L, Houtkooper RH, Moullan N,
Katsyuba E, Ryu D, Cantó C, Mottis A, Jo YS, Viswanathan M,
Schoonjans K, et al: The NAD(+)/sirtuin pathway modulates longevity
through activation of mitochondrial UPR and FOXO signaling. Cell.
154:430–441. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Zhang Y, Zhang M, Dong H, Yong S, Li X,
Olashaw N, Kruk PA, Cheng JQ, Bai W, Chen J, et al: Deacetylation
of cortactin by SIRT1 promotes cell migration. Oncogene.
28:445–460. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Jang KY, Kim KS, Hwang SH, Kwon KS, Kim
KR, Park HS, Park BH, Chung MJ, Kang MJ, Lee DG and Moon WS:
Expression and prognostic significance of SIRT1 in ovarian
epithelial tumours. Pathology. 41:366–371. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Mvunta DH, Miyamoto T, Asaka R, Yamada Y,
Ando H, Higuchi S, Ida K, Kashima H and Shiozawa T: Overexpression
of SIRT1 is associated with poor outcomes in patients with ovarian
carcinoma. Appl Immunohistochem Mol Morphol. Feb 9–2016.(Epub ahead
of print).
|
|
45
|
Shi Y, Huang J, Zhou J, Liu Y, Fu X, Li Y,
Yin G and Wen J: MicroRNA-204 inhibits proliferation, migration,
invasion and epithelial-mesenchymal transition in osteosarcoma
cells via targeting Sirtuin 1. Oncol Rep. 34:399–406.
2015.PubMed/NCBI
|
|
46
|
Li K, Xyu Q, Liu X, Liu Q and Wang M:
Growth inhibition of human hepatocellular carcinoma by miRNA-204
via down-regulation of Bcl-2 and Sirt1 expression. Xi Bao Yu Fen Zi
Mian Yi Xue Za Zhi. 31:168–172. 2015.(In Chinese). PubMed/NCBI
|
|
47
|
Yamakuchi M: MicroRNA regulation of SIRT1.
Front Physiol. 3:682012. View Article : Google Scholar : PubMed/NCBI
|
